Does improved metabolic health and insulin sensitivity following a weight-loss and fitness intervention in sedentary, obese women alter exercise-associated fuel metabolism and incomplete mitochondrial fatty acid oxidation (FAO), as tracked by blood acylcarnitine patterns? r What is the main finding and its importance?
Introduction
Human insulin resistance and type 2 diabetes mellitus (T2DM) are associated with less efficient or incomplete skeletal muscle long-chain fatty acid (LCFA) combustion, and are also characterized by impaired metabolic flexibility (defined as the shift away from LCFA oxidation toward carbohydrate metabolism in response to increased insulin; see, e.g. Mandarino et al. 1996; Kelley et al. 1999; Kelley, 2005; Ukropcova et al. 2005) . These concepts are supported by cross-limb respiratory quotient measurements (Kelley & Simoneau, 1994; Mandarino et al. 1996; Kelley et al. 1999) , reduced exercise-associated whole-body plasma-derived LCFA oxidation in obese T2DM or insulin-resistant versus obese control subjects (Blaak et al. 2000; Mensink et al. 2001 ) and a more limited combustion of isotopically labelled LCFA and entry of the LCFA carbon into the tricarboxylic acid (TCA) cycle in fasted T2DM subjects (Blaak & Wagenmakers, 2002) . There is some evidence that uptake of LCFA is modestly reduced by ß20-30% in insulin-resistant or T2DM muscle during fasting (Kelley & Simoneau, 1994; Blaak & Wagenmakers, 2002) , but this observation is not universal (Kelley et al. 1999) , and in the postprandial state, muscle uptake does not differ (or is increased) relative to control values (i.e. Kelley & Simoneau, 1994; Blaak & Wagenmakers, 2002; van Hees et al. 2011; Moors et al. 2012) . Thus, it is unlikely that reduced tissue uptake of LCFA can explain less complete LCFA muscle oxidation in the insulin-resistant or T2DM state.
The altered fatty acid oxidation in these states is reflected in part by a mismatch between mitochondrial fatty acid oxidation (FAO) in muscle and other tissues, relative to fuel availability ('mitochondrial overload'; Koves et al. 2008) ; this leads to accumulation of lipid derivatives reflective of incomplete β-oxidation. This can manifest in higher intramyocellular lipid in untrained individuals, which is highly correlated with insulin resistance (Jacob et al. 1999; Krssak et al. 1999; Malenfant et al. 2001; McGarry, 2002; Mingrone et al. 2003) . Concentrations of plasma acylcarnitine derivatives and markers of incomplete LCFA β-oxidation are also increased in connection with insulin resistance, T2DM and poor blood sugar control (Genuth & Hoppel, 1981; Inokuchi et al. 1995; Moder et al. 2003; Adams et al. 2009; Mihalik et al. 2010) . We proposed a potential role for acylcarnitines in triggering cell stress pathways associated with insulin resistance (Adams et al. 2009 ), subsequently demonstrating pro-inflammatory actions of long-chain acylcarnitines in monocyte/macrophage cells (Rutkowsky et al. 2014) and inhibitory actions on insulin signalling in cultured muscle cells (Aguer et al. 2015) . In addition to elevations in acylcarnitine accumulation, the lipotoxicity of insulin resistance and T2DM can involve a higher muscle content of diacylglycerol and ceramides, both of which are implicated in inhibition of insulin signalling (reviewed by Coen & Goodpaster, 2012) . Consistent with observations in vivo, incomplete LCFA β-oxidation is more evident in cultured myotubes isolated from obese, insulin-resistant individuals compared with lean control subjects (Aguer et al. 2015) and in insulin-resistant rat myocytes (Koves et al. 2008) , highlighting the clear correlation between aberrant muscle LCFA metabolism and insulin resistance. Despite this and the well-established role of muscle in whole-body insulin-stimulated glucose uptake, no biomarkers or metabolites that specifically reflect muscle LCFA β-oxidation dynamics have been identified. Such biomarkers would provide insight into the connection between fat metabolism and insulin sensitivity and might be useful tools to assess diabetes risk or T2DM severity or to gauge the efficacy of interventions designed to ameliorate muscle insulin resistance. Furthermore, by characterizing muscle-abundant metabolites it may be possible to identify signalling molecules that are involved with local (i.e. neuronal) and systemic (i.e. tissue-to-tissue) cross-talk.
A major challenge to identifying selective biomarkers of muscle LCFA combustion is the paucity of comparative experimental models in which β-oxidation is altered exclusively or predominantly in muscle cells. One approach to identify candidate metabolites is to perform studies that challenge the muscle metabolic machinery to engage fat oxidation. Improvements in muscle mitochondrial function (i.e. more efficient LCFA combustion) and insulin sensitivity would be expected to change the patterns and concentrations of exercise-associated metabolites as reflected in the circulation. To this end, we employed a submaximal acute exercise protocol to characterize exercise-induced plasma acylcarnitines in a human cohort of insulin-resistant, sedentary women before and after a weight-loss and fitness intervention that markedly improved fitness and insulin sensitivity. To maximize our ability to identify changes in plasma metabolites specifically reflective of muscle metabolism, the acute exercise duration (30 min, sampling every 5 min) and moderate intensity [ß40-45% of maximal oxygen consumption (V O 2 peak )] used for metabolite profiling were designed to activate muscle work and lipolysis rapidly and to ensure robust fatty acid oxidation (Romijn et al. 1993; Brooks, 1997) , while minimizing changes in liver β-oxidation (Fery & Balasse, 1983 . It was hypothesized that acute exercise-induced plasma medium-chain fatty acylcarnitines (indices of incomplete LCFA β-oxidation) would be reduced concurrent with improved metabolic fitness and insulin sensitivity. The close link we observed between exercise and plasma acylcarnitine concentrations subsequently led to novel proof-of-principle studies testing whether acylcarnitines could serve as signals to specific peripheral sensory neurons that interrogate the muscle beds. We speculate that metabolite communication plays an important role in providing the CNS with information related to exertional fatigue and exercise duration and intensity.
Methods

Ethical approval and human subjects
Extensive details regarding diet, recruitment, test week protocols and other intervention-associated aspects for this cohort are provided in a recent report of oral glucose tolerance test metabolomics (Campbell et al. 2014) . A succinct summary is provided here. All protocols were approved by the University of California at Davis Institutional Review Board, in alignment with the Declaration of Helsinki, and all subjects provided informed written consent. The study is listed in ClinicalTrials.gov (NCT01494025).
To identify metabolites that are responsive to changes in insulin sensitivity owing to improvements in fitness and body mass following a diet and exercise intervention, obese modestly hyperinsulinaemic 30-to 50-year-old women were recruited from the greater Davis and Sacramento, California communities. All participants were eumenorrhoeic, non-smoking and sedentary (typical planned exercise <30 min per week as self-reported). Body mass index was between 30 and 37.5 kg m −2 , and participants were weight stable (<5% change in body mass over the previous 6 months). Insulin resistance at the time of screening was identified through an overnight-fasted blood glucose and insulin, and an abbreviated oral glucose tolerance test (OGTT; fasting glucose plus a 2 h glucose after consuming a standard 75 g glucose drink). Insulin resistance was defined as one or more of the following: (i) according to the American Diabetes Association guidelines for prediabetes, fasting glucose ࣙ100 and <126 mg dl −1 or 2 h OGTT glucose ࣙ140 and <199 mg dl −1 ; and/or (ii) a target Quantitative Insulin Sensitivity Check Index (QUICKI) score <0.315, Homeostasis Model Assessment (HOMA) >3.67 or logHOMA >0.085. The latter criteria were derived using the upper limit of normal fasting glucose (100 mg dl −1 ) and a serum insulin (15 μU ml −1 ) that approximates the upper value of the third quartile of 72 normoglycaemic men and women tested by the UC Davis Medical Center Pathology Laboratory in the course of establishing their normal ranges for insulin. Exclusion criteria included any clinical signs of infection, chronic disease, personal history of cardiovascular disease, elevated blood pressure (>130/85 mmHg), diabetes, regular medications other than oral contraceptives, and pregnancy or lactation. Sixteen women participated through the first phase of the study; one subject was not compliant with the prescribed diet provided during either test week and was therefore excluded. Three subjects dropped out following test week 1, before or during the weight-loss and exercise intervention, leaving 12 of 15 compliant subjects available for re-examination in test week 2.
Pre-and postintervention test week protocol
Participants completed testing before ('test week 1') and after ('test week 2') an exercise and weight-loss intervention (14-17 weeks) designed to improve fitness and insulin sensitivity (see Campbell et al. 2014 ; briefly described here). During each test week, subjects refrained from exercise and were weight stable at the time of testing. Exercise-associated acylcarnitine patterns Test week diet. To minimize variability in metabolomics that could be influenced by differences in composition of the diet, during test week 1 and test week 2 the participants were provided with lot-matched foods such that they ate identical diets for the test weeks (Campbell et al. 2014) . Diets were prescribed to maintain body mass during the specific test week using the dietary reference intakes equation. Mass was determined daily during test weeks, and small changes in prescription calories were made to maintain body mass within 5%. Study menus were prepared by a registered dietitian using the University of Minnesota's Nutrient Data System for Research (NDS-R) version 2009. Meals were prepared by the Western Human Nutrition Research Center (WHNRC) Metabolic Kitchen and Human Feeding Laboratory using ProNutra software (Viocare Technologies, Inc., Princeton, NJ, USA), guided by the 2005 Dietary Guidelines for Americans. Menus consisted primarily of shelf-stable (e.g. frozen, dried, canned) foods. During test weeks, participants were instructed to eat and drink only what was provided to them and encouraged to eat study meals on site; however, for logistical reasons (e.g. work schedules) many meals were packed 'to go' . Self-reported adherence was determined with daily food diaries.
Resting metabolic rate (RMR).
On day 3 or 4 of each test week, participants reported to the WHNRC Physiology Laboratory for RMR measurements in the morning following a 12 h overnight fast and having refrained from moderate to vigorous physical activity for 24 h. They were made comfortable in a reclining chair and were instructed to sit quietly for 10 min. The subject was fitted with a facemask and RMR measured using indirect calorimetry (Parvo Medics TrueOne 2400 metabolic cart, Sandy, UT, USA). Respiratory gas exchange measurements were made for the next 20-30 min, and the average RMR and respiratory quotient were determined.
Body composition measurements. Weight was measured on an electronic scale to the nearest 0.1 kg with participants in light clothing, all jewelry removed, pockets emptied and shoes removed. Height was measured using a wall-mounted stadiometer. Body fat mass and fat-free mass were measured by dual-energy X-ray absorptiometry (DXA; GE Lunar Prodigy Encore v10.5, Madison, WI, USA). (typically antecubital) . The first blood sample was taken 5 min after the catheter was placed and prior to exercise. After a brief 5 min warm-up involving pedalling without workload, subjects were fitted with headgear and nose-clip for metabolic cart measurements. During test week 1, the tension on the cycle ergometer (Monark 828E, Vansbro, Sweden) was set to elicit an individualized workload (ß64 W, average across all subjects) at 45%V O 2 peak determined from the peak exercise test. Participants pedalled at the appropriate cadence of 50-60 r.p.m. for 30 min. Between 0 and 5 min of exercise, indirect calorimetry values were checked to ensure the subject was working at an intensity of 45% V O 2 peak ; if needed, the workload was slightly adjusted. After verifying the workload, the apparatus was removed until a second calorimetry measurement between 15 and 20 min. Blood was sampled every 5 min throughout the entire protocol, as was HR and rate of perceived exertion. After 30 min, the workload was reduced to 0 W for a 5 min 'cool-down' , during which subjects continued to pedal at a slow pace. After the cool-down period, between 30 and 35 min, participants moved to a chair, where they rested for 15 min (between 35 and 50 min of the protocol). They continued to have blood sampled and HR measured every 5 min throughout. Blood was collected into EDTA Vacutainers (Becton-Dickinson), placed in ice and centrifuged for plasma that was transferred to −80°C. During test week 2, the same regimen was applied, but with the workload on the cycle ergometer matching the individual's test week 1 workload to ensure equal muscle work during each of the time periods.
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Weight-loss and fitness regimen
Subjects were prescribed a self-selected calorie-restricted diet based on the Dietary Guidelines for Americans and using the dietary reference intakes equation to target a 10% body mass loss over 14 weeks (ß500-600 kcal day −1 reduction). A Baecke physical activity questionnaire (Baecke et al. 1982) was administered to assess self-reported physical activity level, with a score of 5 for the lowest activity and 15 for the highest activity related to work, sport/exercise and non-sport leisure categories; we used a score of 7 for calculating maintenance calories. Participants recorded daily food intake in diaries and received weekly counselling from a registered dietitian. Subjects were provided with a daily nutritional supplement (Bayer One-a-Day for Women) to assure adequate intake of essential vitamins and minerals. Body mass was measured weekly. The total length of time for the weight-loss and fitness intervention phase of the study varied from 14 to 17 weeks, necessitated to match test weeks with respect to menstrual phase. As previously reported, we found no association of menstrual phase or blood concentrations of luteinizing hormone or follicle-stimulating hormone with glucose homeostasis and insulin sensitivity indices (Campbell et al. 2014) .
Participants engaged in a prescribed exercise regimen a minimum of four times per week for the duration of the intervention as directed by WHNRC exercise physiologists. Over the first four intervention weeks, participants exercised aerobically 4 days per week for 30 min each (treadmill or cycle ergometer) at an intensity of 60-70% of their maximal HR as determined in thė V O 2 peak test. During intervention weeks 5-8, exercise sessions were increased to 40 min per session, 4 days per week, and during intervention week 9 onward the intensity was increased to a HR of 75% of maximal. Participants wore HR monitors during all exercise sessions to ensure that they were exercising at the appropriate intensity for the prescribed amount of time, with digital information downloaded by Physiology Support Laboratory staff weekly to ensure compliance.
Acylcarnitine analysis
The details of the HPLC-MS acylcarnitine metabolite detection and analysis are presented elsewhere (Minkler et al. 2015a,b) . Briefly, to 10 μl of sample (plus internal standards) was added organic solvents to precipitate salts and proteins. The resulting supernatant was then applied to a mixed-mode, reversed-phase/strong cation-exchange solid-phase extraction plate (Oasis MCX; purchased from Waters Corporation, Milford, MA, USA). Carnitine and acylcarnitines were eluted, evaporated and derivatized with pentafluorophenacyl trifluoromethanesulfonate, then injected into a UHPLC-MS/MS system. Using sequential ion-exchange/reversed-phase chromatography, carnitine and γ-butyrobetaine were eluted in 4 min chromatograms; optimized multiple reaction monitoring transitions were collected for carnitine, d3-carnitine internal standard, butyrobetaine and d3-butyrobetaine internal standard. Acylcarnitines were eluted in 14 min chromatograms, and optimized MRM transitions were collected for 67 acylcarnitine species and 12 acylcarnitine internal standards. Accurately standardized calibrants were used to construct multiple-point calibration curves for accurate, absolute quantification. Low-, medium-and high-quality control samples were used to validate that the analytical accuracy of each determination was within ±15% of the actual value for medium and high values and within ±20% for the lowest values.
Assessment of effects of acylcarnitine and metabolites in dorsal root ganglia (DRG) neurons
All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Utah, and conducted in the Light laboratory. Detailed experimental procedures have been described previously (Light et al. 2008) . In brief, muscle-innervating DRG neurons were labelled with 1,1 -dioctadecyl-3,3,3 ,3 -tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes, D-282). Injections of DiI were made in 7-to 10-day-old male C57/BL6J mice (n = 37 across all preparations) anaesthetized by ice-cold water, after which the gastrocnemius, plantaris, tibialis anterior, biceps femoris and, in some mice, semitendinosus muscles were exposed. Each muscle was carefully injected with 1-3 μl DiI diluted in dimethyl formamide (J. T. Baker, 9221-01). Animals were then returned to their home cages. Around 2 weeks after the DiI injection, animals were killed with an overdose of isoflurane followed by decapitation. Lumbar DRGs ipsilateral to the DiI injection sides were collected into room temperature Hanks' balanced salt solution, digested with 0.25% trypsin (Sigma, #T0303), and triturated in culture medium comprised of MEM (Invitrogen, #51200-038) and 10% fetal bovine serum (Hyclone). Cell suspensions were pre-plated for 1 h to reduce non-neuronal cells, and then plated onto four centre wells of a 24-well plate pretreated with poly-L-lysine (Sigma, P1274) and laminin (BD Biosciences, 254232). After an initial incubation for 45 min, wells were filled with 1 ml 37°C culture medium containing 10 ng ml −1 glial-derived neurotrophic factor (Preprotech, 450-10) and returned to the incubator for 15-20 h before imaging experiments.
For calcium imaging, cultured DRG cells were loaded with 2 μM fura-2 AM fluorescent dye (Molecular Probes, F1221) in culture medium for 45 min and then washed with pH 7.4 oxygenized observation medium containing no additional ATP or lactate (mM: 145 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 1 citrate, 10 glucose, 10 Mes and 10 Hepes). The final volume in each well was 500 μl. Cells were imaged at room temperature using the Meta Imaging Series Metafluor program (Universal Imaging). Across all experiments, each imaging field had 149 ± 3 cells, 27.5 ± 1.5% of which were labelled in retrograde fashion with DiI. These DiI-labelled cells were visualized by their fluorescence emission in response to 546 nm excitation. All the DiI-labelled and non-labelled cells in the fields were imaged and outlined, and their changes in fluorescence intensities (340 nm/380 nm, normalized to a range from 0 to 1) were traced every 2 s during the experiments. At the end of each experiment, cells were treated with 200 nM capsaicin, followed by a wash with observation medium and then a wash with 50 mM KCl. Those responding to KCl are defined as active, live neurons and those positive for a capsaicin response defined as TRPV1 receptor-positive neurons. Acylcarnitines and other metabolites were delivered transiently to the cells using a two-pipette method, with one pipette extracting solution out of the well and another immediately adding new solution back (Light et al. 2008) . The pH 7.4 medium represents a 'resting' level of the metabolites, and the pH 6.6 medium activates most metabolite-responsive neurons (Light et al. 2008) . The C16-and C6-acylcarnitines were aliquoted in DRG observation medium at 10 mM and kept frozen at −80°C; stocks were diluted to 500 μM working stocks at the time of the experiment and then added to pH 7.4 medium to the desired experimental concentrations, as indicated.
All images and data were saved for offline replay and analysis, as described previously (Light et al. 2008) . Only responses of DiI-labelled neurons were analysed, as they represented muscle-innervating cells. Offline data were loaded into a custom-made LabVIEW (National Instruments, Austin, TX, USA)-based ratiometric program for further analysis. The program subtracted baseline variations, computed baseline means and SDs, and compared them with means and SDs during each metabolite addition. A baseline was 30-60 s of imaging prior to the addition of the metabolites. Responses were defined as increases of fura ratios >2 SD above the baseline. From each animal, we cultured four wells of DRG cells. Sample sizes for each treatment, as indicated in the figure legends, represent independent wells.
Statistics and analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). For pre-versus postintervention changes in exercise-associated plasma acylcarnitine concentration, a two-way ANOVA was used to consider effects of intervention, exercise time and exercise × time interactions. Neuron cell-based studies that tested effects of acylcarnitines versus vehicle controls, within chain length, were analysed by Kruskal-Wallis test owing to non-normality of data sets. In neuron studies examining the effect of acylcarnitines at various pH values, a two-way ANOVA was used to compare the effect of pH, acylcarnitine treatments and interactions. A P value < 0.05 was considered to be statistically significant. Values are expressed as means ± SEM.
Results
Body mass loss and improvements in metabolic health indices following a fitness and dieting intervention
We reported previously (Campbell et al. 2014) that the fitness and weight-loss intervention led to significant reductions in body weight and adiposity, with expected marked improvements of fitness (V O 2 peak ) and substantially improved insulin sensitivity (Matsuda index). As planned, weight and a strict diet were maintained during each of the test weeks (Campbell et al. 2014) . Several phenotype parameters related to fitness and exercise fuel combustion are presented for context (Table 1) .
Overnight-fasted plasma acylcarnitine concentrations following weight-loss and fitness intervention
Values for all individual plasma acylcarnitine concentrations in sedentary overnight-fasted insulin resistant subjects (pre-intervention) and in the subjects after becoming metabolically fit and insulin sensitive (postintervention) are provided in Table 2 . Despite significant improvements in metabolic health, there were few differences in fasting plasma acylcarnitine profiles. For instance, there were no significant differences in fasting plasma free carnitine concentration or in plasma acetylcarnitine, a metabolite derived from catabolism of all fuels (fatty acids, some amino acids and pyruvate) that yield acetyl-CoA. Interestingly, there was a significant effect of the fitness and weight-loss intervention to increase the fasting plasma concentration of the carnitine precursor γ-butyrobetaine, when evaluated by two-way ANOVA (Fig. 1) ; the reduction in plasma cis-3,4-methylene-heptanoylcarnitine following intervention was also significant when evaluated as a two-way ANOVA (see Fig. 4 discussion) . Fasting plasma acylcarnitines associated with fatty acid and amino acid metabolism are discussed below in succession.
Fatty acid metabolism and incomplete long-chain fatty acid β-oxidation. We hypothesized that overnight-fasted plasma concentrations of medium-chain acylcarnitines, indices of incomplete LCFA β-oxidation, would be reduced in the more insulin-sensitive, metabolically fit state following the intervention. However, fasting (Campbell et al. 2014 ).
C6-C14 acylcarnitines remained essentially unchanged by the intervention (Table 2 and Fig. 2 ). The same lack of effect of the intervention was observed for the short-chain acyl-CoA derivative butyrylcarnitine (Table 2 and Fig. 2 ), as well as hydroxy-derivatives of medium-chain fatty acids (MCFA) and LCFA that mark incomplete mitochondrial β-oxidation (Table 2) . In distinct contrast to other MCFA-carnitines, intervention was associated with a reduction in concentration of cis-3,4-methylene-heptanoylcarnitine (Fig. 4) . Overnight-fasting plasma concentration of a similar metabolite, cis-3,4-methylene-nonanoylcarnitine, was not significantly impacted by the intervention (Table 2 and Fig. 4) . Notably, the parent LCFA (cis-13,14-methylene-heptadecanoic acid), from which cis-3,4-methylene-heptanoylcarnitine is ultimately derived following partial β-oxidation, appears to be a xenometabolite produced by gut microbes (Libert et al. 2005; Yang et al. 2007) .
Overnight-fasted plasma concentrations of long-chain saturated and unsaturated acylcarnitines (C16 chain length and above) were almost all reduced in the postintervention state (Table 2) . Most apparent were the significant reductions in concentrations of palmitoylcarnitine (C16; P < 0.05, Student's paired t test) and oleoylcarnitine (C18:1; P = 0.05, Student's paired t test). There was a significant intervention effect for palmitoyl-, oleoyl-and linoleoylcarnitine (C18:2; Fig. 5 ). These observations are suggestive of reduced fasting plasma LCFAs that ultimately provide LCFA-CoA substrate for tissue carnitine palmitoytransferase 1 (CPT1).
Amino acid metabolism. Perturbations in BCAA homeostasis as reflected in higher blood BCAA concentrations are evident with deteriorating insulin sensitivity and blood sugar control (reviewed by Adams, 2011; Lynch & Adams, 2014) ; thus, overnight-fasted plasma concentrations of acylcarnitine derivatives of BCAA catabolism were determined. It was anticipated that improved metabolic health following the weight-loss and fitness intervention would alter acylcarnitine markers of BCAA in a manner suggestive of more complete or efficient catabolism, downstream of the BCAA oxidation check-point mitochondrial branched chain ketoacid dehydrogenase complex (BCKDC). However, there were no obvious differences comparing the pre-versus postintervention phases with respect to overnight-fasted plasma concentrations of carnitine derivatives of leucine (isovaleryl-, 3-methylcrotonyl-or 3-methylglutaroyl-, 3-hydroxyisovaleryl-) or isoleucine (2-methylbutyryl-, tigloyl-, methylmalonyl-, propionyl-; Table 2 ). There was a significant intervention effect for one valine derivative (isobutyryl-), which was modestly increased in overnight-fasted plasma with improved fitness and weight loss (Fig. 7, left panels) . Isovaleryl-, 2-methylbutyryland isobutyrylcarnitines (Fig. 7) are derived from CoA metabolites immediately downstream of the BCKDC. J. Zhang and others 
Exercise-associated plasma acylcarnitine patterns
Plasma concentration graphs for all detectable plasma acylcarnitine metabolites are provided in Supplemental Fig. S1 . For brevity, only a subset of acylcarnitines associated with LCFA β-oxidation and BCAA catabolism are presented and discussed. Data are expressed both as absolute concentrations and as a change from the basal, pre-exercise value using each subject's time zero value as 100%. The latter led to substantially less variance in the data, allowing for clear interpretation of intervention-and exercise-associated changes in acylcarnitine metabolism. As anticipated, a submaximal exercise bout designed to engage muscle LCFA oxidation led to significant shifts in a variety of plasma acylcarnitines, reflective of temporal changes in mitochondrial fuel metabolism.
Free carnitine, acetyl-carnitine and γ-butyrobetaine.
Exercise led to an acute reduction in plasma free carnitine concentration in both the pre-and postintervention conditions, most clearly illustrated in the temporal pattern as a percentage of pre-exercise concentration (Fig. 1) . This is likely to reflect utilization of this metabolite to generate acylcarnitine moieties derived from enhanced fuel catabolism and concurrent flux to acyl-CoA metabolites. Free carnitine continued to decrease during the postexercise cool-down period that began following the 30 min sample collection. Plasma acetylcarnitine increased significantly with exercise, and continued to increase even with exercise cessation (Fig. 1) .
As the most abundant acylcarnitine, the increase in acetylcarnitine probably contributed to the concurrent reduction in free carnitine. Plasma concentrations of the carnitine precursor γ-butyrobetaine were reduced acutely by exercise, and its pattern generally was similar to that of free carnitine concentration (Fig. 1) . The temporal patterns for these metabolites did not differ when comparing pre-and postintervention conditions, but as noted above, there was a significant intervention effect for γ-butyrobetaine.
Fatty acid metabolism and incomplete long-chain fatty acid β-oxidation. Exercise led to a rapid and significant increase in plasma concentrations of chain-shortened products of incomplete LCFA β-oxidation, including C6-to C14-acylcarnitines derived from saturated LCFA catabolism (Figs 2 and 3 ). In addition, chain-shortened products of incomplete unsaturated LCFA combustion, such as decenoylcarnitine derivatives, were also generally increased by exercise (Supplemental Fig. S1 ). Butyrylcarnitine (C4) concentrations were also increased by an acute exercise bout (Figs 2  and 3 ). The exercise-increased concentrations of the plasma metabolites cis-3,4-methylene-heptanoylcarnitine and cis-3,4-methylene-nonanoylcarnitine are shown in Fig. 4 . Altogether, these results indicate that changes in most blood MCFA-carnitines were yoked to acute changes in muscle work. Exercise cool-down was accompanied by progressive, sometimes sharp, reductions in these metabolites (i.e. in samples taken at 35 min onward). Notably, plasma concentrations of C4-C12 MCFA-carnitines remained high and stable during the initial 5 min postexercise period, before falling thereafter. A postexercise reduction in plasma C14-carnitine was not clearly demonstrated. Plasma LCFA-carnitines were increased by the acute exercise bout (Figs 5 and 6 ), but in contrast to MCFA-carnitines, the exercise-associated increase was most clearly apparent only in the postintervention conditions (Fig. 6) . Furthermore, upon cessation of exercise, concentrations of most LCFA-carnitines tended to remain elevated or have a slow downward trajectory. The contrasting exercise-associated patterns comparing pre-and postintervention suggest that extramitochondrial metabolism of LCFA (but not intramitochondrial FAO) was altered by the weight loss and improved fitness.
Branched-chain amino acid metabolism. Patterns of BCAA pathway carnitine derivatives stemming from acyl-CoA metabolites produced by the BCKDC suggest an acute reduction in BCAA catabolism during the initial phase of exercise (Fig. 7) . The metabolites 2-methylbutyrylcarnitine (from Ile), isovalerylcarnitine (from Leu) and isobutyrylcarnitine (from Val) were all reduced over the initial 10-15 min exercise bout time frame, after which levels tended to recover. There was no clear effect of fitness and weight-loss intervention on the temporal acute exercise effect. The exercise bout had little effect on BCAA metabolites that are downstream of these metabolites, e.g. tigloyl-carnitine (from 2-methylbutyryl-CoA-derived tigloyl-CoA) or 3-methyl-crotonyl-carnitine, 3-methyl-glutaroyl-carnitine We and others have shown that select acylcarnitines have a variety of cellular bioactivities that may involve increases in intracellular calcium, modulation of protein kinase C, activation of caspase-3 and regulation of ion channels (McCoin et al. 2015a) . Given that the plasma concentrations illustrated that acylcarnitine production is increased with acute exercise, we hypothesize that they (singly or in combination with other metabolites) serve as exertion-sensitive signals to the nerves that interrogate the muscle. As an initial exploration of this hypothesis, the actions of a medium-chain acylcarnitine (C6-carnitine) and long-chain acylcarnitine (C16-carnitine) on activation of somatosensory neurons associated with mouse muscle were tested. DiI-positive neurons isolated from the DRG clearly marked specific neuronal populations innervating muscle that had previously been injected with this dye (Fig. 8A) . These specific neurons were subsequently tracked with respect to activation (rise in intracellular calcium) in response to acylcarnitines applied in the cell bath system, as illustrated in Fig. 8B .
Palmitoylcarnitine at concentrations of 1-10 μM activated a small subpopulation of DRG neurons (ß2.5-5.5%, depending on the experiment; Fig. 8C ). This effect became most apparent, and statistically significant, at a concentration of 10 μM. At higher concentrations, the percent of cells that were activated by C16-carnitine was substantially increased to ß30% at 25 μM and 80% at 50 μM (Fig. 8C ). At all concentrations tested, C6-carnitine had little to no effect on activation of DRG neurons, in contrast to C16-carnitine (Fig. 8C) . Considering that exercise-associated signals to muscle-innervating neurons are likely to involve a complex milieu of metabolites, acylcarnitines were also applied in the presence of lactate and ATP at concentrations and pH conditions similar to those previously used by the Light laboratory to 'mimic' exercise (Light et al. 2008) . In the presence of lactate and ATP alone, neuron activation was triggered and, as previously reported, this increased significantly at lower pH ranges (Fig. 8D) . The presence of acylcarnitines at 10 μM did not further augment this response, and the increase in activated neurons in response to acylcarnitines in the pH 6.6 conditions did not reach statistical significance. In summary, C16-carnitine led to increases in intracellular calcium in a small subset of muscle-innervating DRG neurons ex vivo at the lowest concentrations tested, but C6-or C16-carnitine did not increase the responses of DRG neurons caused by lactate or ATP in the conditions tested. 
Discussion
There is strong evidence that insulin resistance and T2DM are associated with altered mitochondrial fuel management. For instance, these conditions are often associated with mismatched TCA cycle activity relative to increased fatty acid fuel delivery, leading to incomplete FAO in muscle cells (Koves et al. 2008; Aguer et al. 2015) and tissue and blood accumulation of lipid intermediates, such as acylcarnitines (Genuth & Hoppel, 1981; Inokuchi et al. 1995; Moder et al. 2003; Koves et al. 2008; Adams et al. 2009; Mihalik et al. 2010) . Other lipid derivatives, such as diacylglycerols and ceramides, can also build up and may exacerbate insulin resistance in tissues such as liver and muscle (Amati, 2012; Chaurasia & Summers, 2015) . Based on pro-inflammatory actions of chain-shortened acylcarnitines we observed in pilot studies (Adams et al. 2009) , and in light of literature indicating that blockade of CPT1 ameliorates cultured myocyte insulin resistance (Koves et al. 2008) , we proposed the hypothesis that acylcarnitine metabolites are involved with cell stress and inflammation responses associated with insulin resistance (Adams et al. 2009 ). This concept has been supported by experimental evidence in immune and muscle cell culture studies (Rutkowsky et al. 2014; Aguer et al. 2015) , adding to the historic literature suggesting bioactivities of select acylcarnitines (McCoin et al. 2015a) . Thus, understanding the basis of incomplete FAO and its potential consequences, and the potential roles of acylcarnitines as signalling or regulatory metabolites, has important implications for metabolic health. Contributors to the FAO/TCA cycle mismatch in insulin resistance and T2DM may be a reduced capacity of muscle mitochondria and/or lower complete combustion (i.e. He et al. 2001; Kelley et al. 2002; Petersen et al. 2004; Morino et al. 2005; Ritov et al. 2005; Befroy et al. 2007; Mogensen et al. 2007; Schrauwen & Hesselink, 2008 ). Yet, the assertion that mitochondrial dysfunction underlies diabetes phenotypes has been questioned, because isolated mitochondria from insulin-resistant or T2DM individuals can display normal bioenergetics, and the muscle is calculated to have oxidative capacity that far exceeds what is required for maximal ATP generation (see Holloszy, 2009) . Reconciling these various perspectives must take into account several key principles, as follows: (i) studies using isolated mitochondria are provided with fuel and anaplerotic TCA substrates artificially, potentially masking intrinsic perturbations of TCA activity that occur in situ due to 'anaplerotic/cataplerotic stress' (Adams et al. 2009; Fiehn et al. 2010; Zoppi et al. 2010) ; (ii) meeting muscle ATP needs through FAO can take place without full combustion of the fat in the TCA cycle: for any given ATP requirement, one may generate chain-shortened fatty acid metabolites through β-oxidation that do not enter the TCA cycle at all, but simply accumulate or are exported from mitochondria; and (iii) while measuring muscle fibre metabolism ex vivo is an improvement over isolated mitochondria, bioenergetics profiles comparing insulin-resistant and insulin-sensitive preparations will still be strongly influenced by the ATP turnover requirements of the cells, which may differ. With these concepts in mind, we set out to determine whether incomplete LCFA combustion (viz. matching of fuel delivery to TCA activity) is ameliorated in vivo concurrent with robust increases in metabolic fitness and insulin sensitivity in previously sedentary, obese, insulin-resistant women. Secondarily, acylcarnitine patterns related to BCAA catabolism were determined because blood BCAA concentrations correlate to insulin resistance phenotypes, and oxidation of BCAA is regulated in part by FAO (Adams, 2011; Lynch & Adams, 2014) . A submaximal exercise bout and duration designed to trigger muscle work and fat oxidation was leveraged to address these questions.
The first important finding from these studies is that despite marked improvements in insulin sensitivity and fitness, there was no evidence for a difference in the 'completeness' of fasting or exercise-induced intramitochondrial FAO, as defined by plasma concentrations and temporal responses of shortand medium-chain acylcarnitines. This was surprising considering the large body of evidence indicating that in the T2DM or insulin-resistant states, circulating levels of many acylcarnitines, including chain-shortened moieties, are higher (Genuth & Hoppel, 1981; Inokuchi et al. 1995; Moder et al. 2003; Koves et al. 2008; Adams et al. 2009; Mihalik et al. 2010) , and incomplete FAO is observed even in cultured myotubes derived from insulin-resistant models (Koves et al. 2008; Aguer et al. 2015) . Our observations regarding no intervention effects on overnight-fasted, resting plasma medium-chain acylcarnitines are similar to the report of Rodríguez-Gutiérrez et al. (2012) , who studied the effects of a 10 week aerobic exercise intervention in overweight adults. Resting muscle biopsy results from trained (presumably exquisitely insulin-sensitive) individuals displayed increased, not decreased, acylcarnitine content across chain lengths (Huffman et al. 2014) . Together, these published results and ours herein indicate that factors beyond insulin resistance dictate tissue and blood acylcarnitine patterns.
With respect to the metabolic shifts inherent to an acute exercise bout, as expected the blood concentrations of all chain-shortened acylcarnitines were significantly and rapidly increased, indicative of accelerated FAO. In the case of C4-to C12-carnitines, cessation of exercise led to a rapid reduction in their concentrations, as also described by others (i.e. Lehmann et al. 2010; Hansen et al. 2015) . Assuming that during vigorous submaximal exercise the acute changes in blood acylcarnitine patterns track muscle accumulation (Hiatt et al. 1989; Friolet et al. 1994) , we interpret these plasma patterns to indicate that: (i) regardless of insulin sensitivity and fitness status in non-diabetic women, muscle intramitochondrial β-oxidative flux is being driven wholly by ATP turnover (oxidative phosphorylation); and (ii) this process is inherently inefficient in that chain-shortened acylcarnitines increase dramatically with exercise, independent of improvements in fitness and insulin sensitivity. The latter aligns with observations comparing T2DM and non-diabetic subjects during exercise (Hansen et al. 2015) . Teleologically, inefficient FAO during exercise enables rapid flux through β-oxidation to meet increased ATP needs, with acylcarnitine generation supporting continued availability of the finite intramitochondrial coenzyme-A pools that support oxidative metabolism. We conclude that in conditions in which muscle work is held constant, intramitochondrial FAO and the attendant generation of chain-shortened acyl-CoA moieties (reflected in acylcarnitine patterns) are directly tethered to total muscle oxidative phosphorylation (ATP turnover), independent of tissue or whole-body metabolic health. A caveat to this interpretation is that in our fixed-workload model, metabolism was sampled in the postintervention trained subjects at a lower percentage of theirV O 2 peak compared with the pre-intervention state. This would have been accompanied by a greater reliance on fat metabolism to meet ATP needs in the postintervention phase when fitness was significantly improved, as per the 'crossover' concept of Brooks & Mercier (1994) and as illustrated by the modest intervention-associated increase in average exercise bout FAO (14% higher) and reduced carbohydrate oxidation (17% lower) in our subjects. A limitation of the present study is that tracer kinetics or other methods were not used to track tissue-specific and whole-body FAO with a higher degree of definition compared with indirect calorimetry during the dynamic state of acute exercise. Furthermore, although the tight recruitment criteria and controlled nature of the experiments and diets were robust, the small sample size of the cohort may have dampened statistical power to detect stronger intervention-associated differences in fuel choice during exercise. In contrast to the equivalent patterns of shortand medium-chain acylcarnitines in pre-versus postintervention conditions, plasma long-chain acylcarnitines (relative to resting, overnight-fasted levels) were significantly impacted by the intervention. Postintervention, long-chain acylcarnitines increased with acute exercise, whereas pre-intervention exercise-induced responses for LCFA-carnitines were weak, in many cases remaining flat, or modestly and slowly increased. This was not anticipated. We suspect that the increased LCFA-carnitine exercise-associated trajectories following the fitness and weight-loss intervention relates to training effects that would have increased in situ muscle CPT1 activity. The abundance of CPT1 has been reported to be ß25% higher in muscle of endurance-trained versus sedentary individuals (Jong-Yeon et al. 2002) , and muscle activity/expression of malonyl-CoA decarboxylase (an enzyme that degrades the CPT1 inhibitor malonyl-CoA) is increased by training (Kuhl et al. 2006) . Furthermore, training leads to an increase in muscle mitochondrial capacity (i.e. Short et al. 2003; Menshikova et al. 2005 Menshikova et al. , 2007 , and by extension this would yield a higher whole-tissue, resident CPT1 capacity. Unlike the enzymes that control intramitochondrial β-oxidation that generate chain-shortened acyl-CoAs and their acylcarnitine derivatives, CPT1 is not regulated by oxidative phosphorylation and attendant changes in the intramitochondrial NAD + /NADH status. The sharp reduction in plasma LCFA with acute exercise (Supplemental Fig. S2 ) is consistent with enhanced utilization of this substrate from the blood pool. In the face of increased LCFA delivery to exercising muscle, higher whole-muscle CPT1 activity following a weight-loss and training intervention would drive greater increases in long-chain acylcarnitine generation and export, as suggested by the results herein. The postulate that intervention-associated increases in exercise-induced LCFA-carnitines reflect the muscle bed CPT1 activity will require additional biopsy-based studies to validate. Interestingly, in the overnight-fasted, resting state there was a significant reduction in the concentration of several LCFA-carnitines following the weight-loss and training intervention. The physiological ramifications of intervention effects on resting-and exercise-associated plasma LCFA-carnitines are not clear. The possibility that differential LCFA-carnitine myocyte and mitochondrial accumulation influences muscle cell stress, myokine production (i.e. interleukin-6), ion transporters and other activities is worth considering (McCoin et al. 2015a,b) . Long-chain acylcarnitines and other exercise-associated metabolites (singly or in combination) also have the potential to serve as signalling metabolites to neurons, communicating information from the muscle bed, as discussed below.
In addition to fatty acid metabolism, acylcarnitine profiling provided insights regarding the mitochondrial catabolism of BCAA fuels during exercise before and after the fitness and weight-loss intervention. Of particular interest is the question of whether or not improvements in metabolic health lead to changes in BCAA metabolism, because modest elevations in fasting blood BCAA concentrations track and predict insulin resistance and T2DM risk (reviewed by Adams, 2011; Lynch & Adams, 2014) . In the present experiment, plasma carnitine derivatives of BCAA-derived CoA metabolites just downstream of the rate-limiting enzyme complex in the mitochondrial BCAA catabolism pathway (BCKDC) were largely unaffected by the training and weight-loss intervention, despite marked improvement in insulin sensitivity. These data are consistent with BCAA metabolite profiling in this cohort (Campbell et al. 2014) and in a separate weight-loss cohort (Piccolo et al. 2015) ; in those studies, there was no evidence from plasma BCAA or branched-chain ketoacid patterns that intervention-associated improvements in insulin sensitivity altered BCAA catabolism pathways. Indeed, the commonly reported correlation between blood BCAA and insulin resistance indices seems to be lost upon weight-loss intervention (Petersen et al. 2012; Piccolo et al. 2015) . Thus, the results highlight once again that the link between insulin resistance and circulating BCAA concentrations (and perhaps BCKDC) are context specific. It is notable that there was an intervention effect for the valine-derived metabolite isobutyrylcarnitine, which was increased by the weight-loss and training intervention. The basis for this unique profile is not clear but suggests differential catabolic flux of valine. From a technical standpoint, it is worth noting that the acylcarnitine analytical methods used herein are superior to tandem MS because isobutyrylcarnitine and butrylcarnitine could be distinguished; these metabolites changed in opposite directions during the exercise bout, underscoring that they each have different fuel precursors. Recently, elegant studies by Arany and colleagues pointed to 3-hydroxyisobutyrate (a metabolite downstream of isobutryl-CoA) as a paracrine factor promoting muscle fatty acid uptake and insulin resistance (Jang et al. 2016) .
Our results showing no effect of improved metabolic fitness and insulin sensitivity on plasma leucine and isoleucine acylcarnitine derivatives and an increase in a valine catabolic derivative in these conditions highlight the equivocal nature of the association between BCAA and insulin resistance. A second important finding related to BCAA catabolism was that exercise-induced temporal patterns of acylcarnitines reflective of BCKDC activity differed among the specific BCAA derivatives. For instance, the concentration of the leucine/2-ketoisocaproate derivative isovalerylcarnitine was rapidly reduced with acute exercise, and the isoleucine/2-keto-methylvalerate derivative 2-methylbutyrylcarnitine displayed a similar reduction but less marked and more delayed. The transient reduction in these metabolites is likely to reflect acute inhibition of the BCKDC by increased FAO (Corkey et al. 1982 ; also see Adams, 2011) . Concentrations of these metabolites recovered partly or completely as exercise continued, and the valine/2-ketoisovalerate derivative isobutyrylcarnitine was variably impacted by exercise. It is not immediately clear why there are differing patterns of metabolites associated with each of the individual BCAAs; differences in availability of substrate branched-chain ketoacids or differing biochemical activities of the specific enzymes downstream of BCKDC in situ may be considered. Overall, we conclude that the BCAA derivative acylcarnitine patterns support the idea that activation of FAO acutely downregulates the oxidative flux of BCAA during an exercise bout. An exciting finding was that the weight-loss and training intervention led to significant changes in the concentration of metabolites associated with gut microbiome metabolism ('non-self' xenometabolites). In other words, host health impacted gut microbiome metabolism, as we have highlighted in a previous paper There was a significant effect of pH/lactate/ATP treatments on neuron activation (P < 0.0001; two-way ANOVA), but no significant interaction with acylcarnitines. Sample sizes varied by condition and treatment, as follows: C, C6-carn studies, n = 20, 3, 5, 3, 4 and 5 (vehicle, 1, 5, 10, 25 and 50 μM, respectively); C16-carn studies, n = 27, 4, 5, 8, 6 and 4 (vehicle, 1, 5, 10, 25 and 50 μM, respectively); and D, at pH 7.4, 7.2, 7.0, 6.8 and 6.6, respectively, n = 10, 6, 15, 11 and 3 (vehicle) ; n = 23, 4, 5, 6 and 8 (C6-carn); and n = 18, 4, 4, 5 and 6 (C16-carn). * * P < 0.01; ‡ P < 0.001 compared with vehicle, Kruskal-Wallis test. Exercise-associated acylcarnitine patterns stemming from this cohort (Campbell et al. 2014) .
Extending those results, in the present study plasma cis-3,4-methylene-heptanoylcarnitine was significantly reduced in the postintervention conditions; this metabolite is a medium-chain derivative of a long-chain fatty acid that is almost certainly a xenometabolite. Acylcarnitine fatty acid metabolites with a cyclopropane ring reportedly disappeared in the urine of humans treated with the antibiotic adriamycin and were not detectable in urine from newborns (Libert et al. 2005) , suggestive of a gut microbe origin for the parent long-chain acyl group. It is proposed that cis-3,4-methylene-heptanoylcarnitine emanates from incomplete β-oxidation of cis-13, 14-methylene-heptadecanoic acid, a product of bacterial metabolism (also see Yang et al. 2007) . A strength of the present study is that metabolomics evaluations were conducted with a controlled feeding protcol, in which individuals were fed the same diets (Campbell et al. 2014) . These results support the concept that improved metabolic health and weight loss modify the gut microbe ecology and metabolism through host-derived signals independent of diet (Campbell et al. 2014) .
We also observed an intervention-associated increase in the co-metabolite (having potentially both microbial and host origin) γ-butyrobetaine, a carnitine pathway intermediate whose circulating concentrations can be impacted by gut microbial metabolism of dietary carnitine (Koeth et al. 2014) . However, the idea that intervention-associated changes in this metabolite were attributable to microbiome alterations is tempered by the fact that γ-butyrobetaine can also be derived from endogenous enzyme activities, starting with trimethyllysine made available through protein breakdown/turnover (Hoppel & Davis, 1986) . Further research is warranted to explore how host metabolic health influences gut microbe metabolism and the resulting xenometabolome, to elucidate how these metabolites are stored and transported in the body and to understand which xenometabolites display tissue bioactivities. A final set of observations involved the question of whether or not muscle metabolites serve as exertion signals to somatosensory afferent neurons that interrogate muscle beds. If true, such factors could inform the CNS and/or motor neurons regarding muscle workload, fuel homeostasis, fatigue and muscle conditions. As an initial evaluation of acylcarnitines as candidate exertion signals, we conducted proof-of-principle studies looking at effects of C6-(medium-chain) and C16-carnitine (long-chain) metabolites on activation of muscle-innervating mouse dorsal root ganglia neurons. In the absence of lactate and ATP metabolites known to trigger these cells (Light et al. 2008 ), 1-10 μM palmitoylcarnitine activated a small subset of neurons (ß2.5-5.5%), as indicated by increased intracellular Ca 2+ , in contrast to hexanoylcarnitine, which had little to no effect at any concentration. We speculate that the very high activation rates observed at 25-50 μM C16-carnitine were attributable to perturbations in the neuronal membranes because of the zwitterionic nature of this metabolite (McCoin et al. 2015a) . The biochemical milieu surrounding muscle during exercise does not consist of single metabolites in isolation, which may explain the modest activation at potentially physiological levels (C16-carnitine) or lack thereof at any concentration in the case of C6-carnitine. A mixture of metabolites and changes in pH used previously to model the muscle biochemistry of modest to significant exertion (Light et al. 2008) activated DRG neurons, with increasing populations of cells engaged as pH was lowered into ranges (mid-6s) typically reported during modest to exhaustive exercise (Sahlin et al. 1976; Costill et al. 1982; Katz et al. 1984) . This effect was not clearly augmented by the presence of acylcarnitines in the present conditions. We cannot fully exclude the possibility that effects of C16-carnitine on neurons were attributable to provision of metabolizable energy; however, countering this perspective is the fact that C6-carnitine did not trigger DRG neurons, and only a small subset of neurons were responsive at lower concentrations of C16-carnitine, which suggests specificity. Certainly, the ex vivo neuron results using C16-carnitine singly, coupled to the close association between muscle work and acylcarnitine production, support the further study of acylcarnitines and other muscle-derived metabolites as fatigue or exertion signals involved in a muscle-somatosensory-CNS communication system. Such studies should also consider additional chain lengths, including more abundant acylcarnitines. The potential that such a system impacts the muscle-somatosensory-motor neuron short loop is also intriguing to consider. Given that the concentrations of acylcarnitines around the muscle-neuron interface are not yet known, the physiological relevance of the present observations remains a question to be answered in future experiments.
In summary, we have performed the most comprehensive assessment to date of human blood acylcarnitine patterns in response to acute exercise and a weight-loss and training intervention, during a controlled feeding period designed to minimize the diet-associated influence on the metabolome and microbiome. The results highlight that improved metabolic health failed to alter markers of incomplete LCFA β-oxidation at rest or during a standard exercise bout that engaged equivalent levels of muscle work. This strongly suggests that that intramitochondrial generation of chain-shortened acylcarnitines in exercising muscle is tethered closely to the absolute amount of oxidative phosphorylation (ATP turnover). Furthermore, we confirmed prior observations in this group of women that weight loss, improved fitness and insulin sensitivity alter xenometabolites or their derivatives in the body, indicating that host metabolic status drives changes in gut microbe metabolism, even in controlled feeding conditions. Finally, a proof-of-principle study revealed an exciting new finding; namely, that palmitoylcarnitine can activate muscle-innervating somatosensory afferents. This raises the intriguing possibility that myocyte acylcarnitine and other metabolites responsive to exercise serve as signalling metabolites to neurons that inform the brain about exertion, muscle work level and duration and fuel utilization.
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Supplemental Figure S1 . Temporal concentration patterns of plasma acylcarnitines during an acute 30 min exercise bout of ß45% ofV O 2 peak in sedentary, obese, insulin-resistant women before and after a weight-loss and fitness intervention. Values are expressed as the percentage of time zero (before exercise) concentrations that are provided in Table 2 of the manuscript. Values are the mean ± SEM (n = 15, pre-intervention; n = 12 postintervention); in some cases, outliers were removed. Supplemental Figure S2 . Temporal concentration patterns of plasma long-chain fatty acids during an acute 30 min exercise bout of ß45% ofV O 2 peak in sedentary, obese, insulin-resistant women before and after a weight-loss and fitness intervention. Values are the mean ± SEM (n = 15, pre-intervention; n = 12 postintervention), and values are in quantifier peak ion abundances (from 'global metabolomics' analysis; for methods, see Campbell et al. 2014) .
